Does the media prefer IDXX or NVST?

In the previous week, Envista had 6 more articles in the media than IDEXX Laboratories. MarketBeat recorded 15 mentions for Envista and 9 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.17 beat Envista's score of 1.02 indicating that IDEXX Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Envista 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ISRG or IDXX?

In the previous week, Intuitive Surgical had 17 more articles in the media than IDEXX Laboratories. MarketBeat recorded 26 mentions for Intuitive Surgical and 9 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.17 beat Intuitive Surgical's score of 0.98 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intuitive Surgical 19 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SYK or IDXX?

Stryker has higher revenue and earnings than IDEXX Laboratories. Stryker is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stryker $25.12B 5.04 $3.25B $9.65 34.21 IDEXX Laboratories $4.30B 10.13 $1.06B $14.22 38.92

Does the media prefer SYK or IDXX?

In the previous week, Stryker had 66 more articles in the media than IDEXX Laboratories. MarketBeat recorded 75 mentions for Stryker and 9 mentions for IDEXX Laboratories. Stryker's average media sentiment score of 1.54 beat IDEXX Laboratories' score of 1.17 indicating that Stryker is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stryker 70 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive IDEXX Laboratories 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IDXX or MDT?

In the previous week, Medtronic had 36 more articles in the media than IDEXX Laboratories. MarketBeat recorded 45 mentions for Medtronic and 9 mentions for IDEXX Laboratories. Medtronic's average media sentiment score of 1.36 beat IDEXX Laboratories' score of 1.17 indicating that Medtronic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medtronic 35 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BSX or IDXX?

In the previous week, Boston Scientific had 61 more articles in the media than IDEXX Laboratories. MarketBeat recorded 70 mentions for Boston Scientific and 9 mentions for IDEXX Laboratories. Boston Scientific's average media sentiment score of 1.43 beat IDEXX Laboratories' score of 1.17 indicating that Boston Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 48 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Positive IDEXX Laboratories 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IDEXX Laboratories (IDXX) Competitors

$553.44 +3.43 (+0.62%)

As of 04:00 PM Eastern

Compare

IDXX vs. NVST, ISRG, SYK, MDT, and BSX

Should you buy IDEXX Laboratories stock or one of its competitors? IDEXX Laboratories's main competitors and comparable companies include Envista (NVST), Intuitive Surgical (ISRG), Stryker (SYK), Medtronic (MDT), and Boston Scientific (BSX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does IDEXX Laboratories compare to Envista?

IDEXX Laboratories (NASDAQ:IDXX) and Envista (NYSE:NVST) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 1.0% of Envista shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Envista had 6 more articles in the media than IDEXX Laboratories. MarketBeat recorded 15 mentions for Envista and 9 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.17 beat Envista's score of 1.02 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Envista	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEXX Laboratories has higher revenue and earnings than Envista. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	10.13	$1.06B	$14.22	38.92
Envista	$2.72B	1.64	$47M	$0.58	47.86

IDEXX Laboratories currently has a consensus target price of $747.00, indicating a potential upside of 34.97%. Envista has a consensus target price of $29.31, indicating a potential upside of 5.58%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, equities analysts plainly believe IDEXX Laboratories is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.50

IDEXX Laboratories has a net margin of 25.03% compared to Envista's net margin of 3.33%. IDEXX Laboratories' return on equity of 71.96% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	25.03%	71.96%	33.60%
Envista	3.33%	7.88%	4.33%

IDEXX Laboratories has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Envista has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Summary

IDEXX Laboratories beats Envista on 12 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Intuitive Surgical currently has a consensus target price of $508.68, suggesting a potential upside of 37.33%. IDEXX Laboratories has a consensus target price of $747.00, suggesting a potential upside of 34.97%. Given Intuitive Surgical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Intuitive Surgical is more favorable than IDEXX Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	8 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.68
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

Intuitive Surgical has higher revenue and earnings than IDEXX Laboratories. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.06B	13.00	$2.86B	$8.73	42.43
IDEXX Laboratories	$4.30B	10.13	$1.06B	$14.22	38.92

In the previous week, Intuitive Surgical had 17 more articles in the media than IDEXX Laboratories. MarketBeat recorded 26 mentions for Intuitive Surgical and 9 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.17 beat Intuitive Surgical's score of 0.98 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	19 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.6% of Intuitive Surgical shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 0.6% of Intuitive Surgical shares are held by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Intuitive Surgical has a net margin of 28.45% compared to IDEXX Laboratories' net margin of 25.03%. IDEXX Laboratories' return on equity of 71.96% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.45%	16.91%	14.83%
IDEXX Laboratories	25.03%	71.96%	33.60%

Intuitive Surgical has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Summary

Intuitive Surgical beats IDEXX Laboratories on 9 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Stryker?

Stryker (NYSE:SYK) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

77.1% of Stryker shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Stryker had 66 more articles in the media than IDEXX Laboratories. MarketBeat recorded 75 mentions for Stryker and 9 mentions for IDEXX Laboratories. Stryker's average media sentiment score of 1.54 beat IDEXX Laboratories' score of 1.17 indicating that Stryker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stryker	70 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
IDEXX Laboratories	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stryker has higher revenue and earnings than IDEXX Laboratories. Stryker is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$25.12B	5.04	$3.25B	$9.65	34.21
IDEXX Laboratories	$4.30B	10.13	$1.06B	$14.22	38.92

Stryker has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

IDEXX Laboratories has a net margin of 25.03% compared to Stryker's net margin of 14.43%. IDEXX Laboratories' return on equity of 71.96% beat Stryker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stryker	14.43%	23.63%	11.39%
IDEXX Laboratories	25.03%	71.96%	33.60%

Stryker currently has a consensus price target of $386.28, suggesting a potential upside of 17.03%. IDEXX Laboratories has a consensus price target of $747.00, suggesting a potential upside of 34.97%. Given IDEXX Laboratories' higher possible upside, analysts clearly believe IDEXX Laboratories is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.79
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

IDEXX Laboratories beats Stryker on 9 of the 17 factors compared between the two stocks.

How does IDEXX Laboratories compare to Medtronic?

IDEXX Laboratories (NASDAQ:IDXX) and Medtronic (NYSE:MDT) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

IDEXX Laboratories presently has a consensus target price of $747.00, suggesting a potential upside of 34.97%. Medtronic has a consensus target price of $98.83, suggesting a potential upside of 7.24%. Given IDEXX Laboratories' higher probable upside, equities analysts plainly believe IDEXX Laboratories is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Medtronic	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67

IDEXX Laboratories has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Medtronic had 36 more articles in the media than IDEXX Laboratories. MarketBeat recorded 45 mentions for Medtronic and 9 mentions for IDEXX Laboratories. Medtronic's average media sentiment score of 1.36 beat IDEXX Laboratories' score of 1.17 indicating that Medtronic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medtronic	35 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medtronic has higher revenue and earnings than IDEXX Laboratories. Medtronic is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	10.13	$1.06B	$14.22	38.92
Medtronic	$36.36B	3.24	$4.80B	$3.73	24.71

IDEXX Laboratories has a net margin of 25.03% compared to Medtronic's net margin of 13.20%. IDEXX Laboratories' return on equity of 71.96% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	25.03%	71.96%	33.60%
Medtronic	13.20%	14.51%	7.76%

Summary

IDEXX Laboratories beats Medtronic on 10 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

IDEXX Laboratories has a net margin of 25.03% compared to Boston Scientific's net margin of 17.50%. IDEXX Laboratories' return on equity of 71.96% beat Boston Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.50%	19.28%	10.89%
IDEXX Laboratories	25.03%	71.96%	33.60%

Boston Scientific presently has a consensus price target of $71.62, suggesting a potential upside of 48.52%. IDEXX Laboratories has a consensus price target of $747.00, suggesting a potential upside of 34.97%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than IDEXX Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	2 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.71
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Boston Scientific has higher revenue and earnings than IDEXX Laboratories. Boston Scientific is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07B	3.48	$2.90B	$2.47	19.52
IDEXX Laboratories	$4.30B	10.13	$1.06B	$14.22	38.92

In the previous week, Boston Scientific had 61 more articles in the media than IDEXX Laboratories. MarketBeat recorded 70 mentions for Boston Scientific and 9 mentions for IDEXX Laboratories. Boston Scientific's average media sentiment score of 1.43 beat IDEXX Laboratories' score of 1.17 indicating that Boston Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	48 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Positive
IDEXX Laboratories	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Boston Scientific has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

Summary

Boston Scientific and IDEXX Laboratories tied by winning 8 of the 16 factors compared between the two stocks.

Get IDEXX Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDXX vs. The Competition

Export

Metric	IDEXX Laboratories	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$43.33B	$5.94B	$7.40B	$12.81B
Dividend Yield	N/A	1.75%	2.53%	11.02%
P/E Ratio	38.92	21.41	212.23	20.76
Price / Sales	10.13	69.39	630.33	94.71
Price / Cash	36.46	33.21	79.89	53.65
Price / Book	27.04	6.24	13.14	6.20
Net Income	$1.06B	$149.10M	$3.47B	$348.07M
7 Day Performance	-1.56%	0.53%	1.38%	0.67%
1 Month Performance	1.68%	9.26%	8.62%	4.84%
1 Year Performance	-13.76%	6.82%	25.90%	16.83%

IDEXX Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDXX IDEXX Laboratories	4.4418 of 5 stars	$553.44 +0.6%	$747.00 +35.0%	-14.2%	$43.33B	$4.30B	38.92	11,000	Positive News
NVST Envista	3.0385 of 5 stars	$27.68 -1.4%	$29.31 +5.9%	+30.1%	$4.51B	$2.72B	47.72	12,000	Insider Trade
ISRG Intuitive Surgical	4.5318 of 5 stars	$390.33 -1.1%	$508.68 +30.3%	-20.6%	$139.37B	$10.06B	44.71	17,021
SYK Stryker	4.9727 of 5 stars	$331.75 -2.2%	$386.28 +16.4%	-15.3%	$130.11B	$25.12B	34.38	56,000	Positive News Insider Trade
MDT Medtronic	4.7801 of 5 stars	$90.44 -0.9%	$98.83 +9.3%	-0.9%	$116.83B	$36.36B	24.25	95,000	Trending News Upcoming Earnings Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDXX) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEXX Laboratories (IDXX) Competitors

IDXX vs. NVST, ISRG, SYK, MDT, and BSX

How does IDEXX Laboratories compare to Envista?

Summary

How does IDEXX Laboratories compare to Intuitive Surgical?

Summary

How does IDEXX Laboratories compare to Stryker?

Summary

How does IDEXX Laboratories compare to Medtronic?

Summary

How does IDEXX Laboratories compare to Boston Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDXX vs. The Competition

IDEXX Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEXX Laboratories (IDXX) Competitors

IDXX vs. NVST, ISRG, SYK, MDT, and BSX

How does IDEXX Laboratories compare to Envista?

Do institutionals and insiders believe in IDXX or NVST?

Does the media prefer IDXX or NVST?

Which has stronger earnings & valuation, IDXX or NVST?

Do analysts recommend IDXX or NVST?

Is IDXX or NVST more profitable?

Which has more volatility and risk, IDXX or NVST?

Summary

How does IDEXX Laboratories compare to Intuitive Surgical?

Do analysts recommend ISRG or IDXX?

Which has higher valuation and earnings, ISRG or IDXX?

Does the media prefer ISRG or IDXX?

Do institutionals & insiders have more ownership in ISRG or IDXX?

Is ISRG or IDXX more profitable?

Which has more volatility & risk, ISRG or IDXX?

Summary

How does IDEXX Laboratories compare to Stryker?

Do institutionals and insiders hold more shares of SYK or IDXX?

Does the media prefer SYK or IDXX?

Which has preferable valuation & earnings, SYK or IDXX?

Which has more volatility and risk, SYK or IDXX?

Is SYK or IDXX more profitable?

Do analysts recommend SYK or IDXX?

Summary

How does IDEXX Laboratories compare to Medtronic?

Do analysts rate IDXX or MDT?

Which has more risk and volatility, IDXX or MDT?

Do insiders and institutionals hold more shares of IDXX or MDT?

Does the media favor IDXX or MDT?

Which has better earnings & valuation, IDXX or MDT?

Is IDXX or MDT more profitable?

Summary

How does IDEXX Laboratories compare to Boston Scientific?

Is BSX or IDXX more profitable?

Do analysts rate BSX or IDXX?

Do insiders & institutionals have more ownership in BSX or IDXX?

Which has stronger valuation & earnings, BSX or IDXX?

Does the media prefer BSX or IDXX?

Which has more risk & volatility, BSX or IDXX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDXX vs. The Competition

IDEXX Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools